Clinical research that moves medicine

Research into transcranial direct-current stimulation in epilepsy patients has given us an invaluable insight.

Back in 2006 Dr Felipe Fregni, head of the laboratory for neuromodulation at the Spaulding Rehabilitation Hospital, Boston/USA and his team noted that a 20-minute stimulation with 1 mA significantly reduced brain patterns typical of epilepsy in the brains of pharmacoresistant patients with focal or multifocal epilepsy, as the EEG showed. The frequency of seizures also tended to fall. These effects continued beyond the stimulation time.

(Source: Fregni F, Thome-Souza S, Nitsche MA, Freedman SD, Valente KD, Pascual-Leone A. A controlled clinical trial of cathodal DC polarization in patients with refractory epilepsy. Epilepsia 2006; 47(2):335e42.)

From insight to technology transfer

What countless other studies in recent years have found is that transcranial electrical stimulation of the brain opens new therapy options for neurological and psychiatric diseases, where modulation of the stimulation originating in the cortex of the brain is the key factor. These stimulation procedures could affect, for instance, severe depression, migraine or chronic pain.

The experts at Precisis AG, in collaboration with reference centres and scientific research groups, used this knowledge and have turned it into actual, medical technology applications. Our focus is initially epilepsy, the treatment of which we wish to expand and facilitate with the EASEE® system we have developed. Other applications are in the pipeline.

Our EASEE® studies

After successful studies in animals and healthy volunteers, an initial short-term study carried out in an outpatient setting with epilepsy patients in 2016/2017 showed that the EASEE® stimulation works well and is well-tolerated. All patients who wore the EASEE® platelet electrodes on an hourly basis on their scalps tolerated the stimulation method well.

The clinical trial with selected patients with therapy-resistant focal epilepsy should confirm the mode of action of long-term neuromodulation, the principle on which the EASEE® system is based. The multicentre study is to be carried out in 2018 in about ten epilepsy centres across Europe.